MedTrace Logo

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-05-11

No results posted yet for this study

Summary

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DRUG

APVO436

Infusion drug administered as a 4 hour infusion.

DRUG

Venetoclax

Oral tablet given on days 1 through 22, of a 28 day cycle.

DRUG

Azacitidine

Intravenous infusion given on days 1-8 of a 28 day cycle

Sponsors & Collaborators

  • Aptevo Therapeutics

    lead INDUSTRY

Principal Investigators

  • Dirk Huebner, MD · Aptevo Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2027-10-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06634394 on ClinicalTrials.gov